Children with acute leukemia: A comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation

Pediatric Blood and Cancer

Volumn 56, Issue 1, 2011, Pages 143-151

  Lin, Yu Feng ^a,b   Lairson, David R ^b   Chan, Wenyaw ^b   Du, Xianglin L ^b   Leung, Kathryn S ^a   Kennedy Nasser, Alana A ^a   Martinez, Caridad A ^a   Heslop, Helen E ^a   Brenner, Malcolm K ^a   Krance, Robert A ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Acute leukemia; BMT; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; CYCLOSPORIN A; METHOTREXATE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEUTROPHIL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; THROMBOCYTE; TREATMENT OUTCOME; VIRUS INFECTION;

ACUTE DISEASE; ADOLESCENT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIESIS; HUMANS; INFANT; INFANT, NEWBORN; KINETICS; LEUKEMIA; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 78649675369     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22677     Document Type: Article

References (27)

1. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175-181.
2. Vigorito AC, Azevedo WM, Marques JFC, et al. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998; 22: 1145-1151.
3. Mahmoud HK, Fauser OA, Kami A, et al. Peripheral blood vs. bone marrow as a source for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355-358.
4. Sufliarska S, Horakova J, Bodova I, et al. Allogeneic peripheral blood stem cell transplantations in children-A single center experience. Neoplasma 2004; 51: 110-116.
5. Tanimoto TE, Yamaguchi T, Tanaka Y, et al. Comparative analysis of clinical outcomes after allogeneic bone marrow transplantation versus peripheral blood stem cell transplantation from a related donor in Japanese patients. Br J Haematol 2004; 125: 480-493.
6. Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 2001; 98: 1739-1745.
7. Ringden O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from unrelated donors: A comparison with marrow transplantation. Blood 1999; 94: 455-464.
8. Russell JA, Larratt L, Brown C, et al. Allogeneic blood stem cell and bone marrow transplantation for acute myelogenous leukemia and myelodysplasia: Influence of stem cell source on outcome. Bone Marrow Transplant 1999; 24: 1177-1183.
9. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomized trial. Lancet 2000; 355: 1231-1237.
10. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a resource of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702-3709.
11. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525-1531.
12. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872-4880.
13. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
14. Hongeng S, Krance RA, Bowman LC, et al. Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet 1997; 350: 767-771.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496-509.
17. Rosthoj S, Andersen PK, Abildstrom SZ. SAS macros for estimation of the cumulative incidence functions based on a Cox regression model for competing risks survival data. Comput Methods Programs Biomed 2004; 74: 69-75.
18. Cox DR. Regression models and life-tables. J R Stat Soc (Series B) 1972; 34: 187-220.
19. Cutler C, Giri S, Jeyapalan S, et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: A meta-analysis. J Clin Oncol 2001; 19: 3685-3691.
20. Horan JT, Liesveld JL, Fernandez ID, et al. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: Meta-analysis of randomized controlled trials. Bone Marrow Transplant 2003; 32: 293-298.
21. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the national marrow donor program. Blood 2000; 95: 2219-2225.
22. Craddock C, Szydlo RM, Dazzi F, et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: The case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 112: 228-236.
23. Nichols WG, Corey L, Gooley T, et al. High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: Evidence for indirect effects of primary CMV infection. J Infect Dis 2002; 185: 273-282.
24. Nachbaur D, Clausen J, Kircher B. Donor cytomegalovirus seropositivity and the risk of leukemic relapse after reduced-intensity transplants. Eur J Haematol 2006; 76: 414-419.
25. Behrendt CE, Rosenthal J, Bolotin E, et al. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009; 15: 54-60.
26. Kumar P, Defor TE, Brunstein C, et al. Allogeneic hematopoietic stem cell transplantation in adult acute lymphocytic leukemia: Impact of donor source on survival. Biol Blood Marrow Transplant 2008; 14: 1394-1400.
27. Zuha R, Gatt A, Alvares C, et al. Recipient of CMV seropositivity predicts relapse post allogeneic transplantation in children. Blood 2004; 104 (Abstract 5140).